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In animal models of IgA nephropathy, the inevitable
endogenous immune response to passively administered
antigens alone or in complex with specific IgA mask the exact
role each might play in pathogenesis. To delineate the role
the immune response might play, we have developed a
passive model with exclusive IgA-immune complex-mediated
nephropathy in B-cell-deficient (BCD) mice. Glomerular IgA
immune deposits were induced by administration of purified
IgA antiphosphorylcholine and the specific pneumococcal
C-polysaccharide (PnC) antigen daily for 2 weeks into BCD
and wild-type (WT) mice. In BCD mice IgAþ PnC deposits
induced severe glomerular injury and renal dysfunction. In
contrast, WT mice developed intense glomerular IgG and IgM
and C3 co-deposits of the IgAþ PnC with significantly less
renal injury. Cytofluorometric analysis revealed that PnC
induced in BCD, but not in WT, a rapid and dramatic increase
in number of activated CD3þ /CD69þ T-cell population. The
nuclear factor-kappa B (NF-jB) transcription factor was
activated early and progressively increased in response to
glomerular IgAþPnC deposits. These results suggest that
nephritogenic IgAþ PnC immune deposits induce glomerular
and renal dysfunction through activation of the NF-jB. This
inflammatory pathway is modulated by the endogenous
cellular and antibody response to the antigen affecting the
course of IgA nephropathy progression.
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IgA nephropathy (IgAN) is the most common form of
glomerulonephritis (GN) worldwide.1 The onset of IgAN
may be associated with an upper respiratory tract infec-
tion. Demonstration of a predominant glomerular IgA
deposition in the renal biopsy is essential to establish a
definitive diagnosis of IgAN. Frequently, C3 and other classes
of immunoglobulin deposits are detected in a pattern similar
to the IgA. The most common histopathologic alterations
include focal or diffuse expansion of mesangial regions with
proliferative cells and extracellular matrix. Additionally, a
wide variety of lesions may be seen in patients with more
severe lesions, including diffuse endocapillary proliferation,
segmental sclerosis, segmental necrosis, and cellular crescent
formation.2,3
Although IgAN is considered an immune complex disease
resulting from IgA-immune complex (IgA-IC) glomerular
damage,2 the cause of the disease and the pathogenic
mechanisms that propagate this disease are unknown. Several
experimental models of IgAN have been insightful in
describing different mechanisms for induction and progres-
sion of the disease.4–9 In these models, usually IgG and IgM
deposits accompany and may even exceed the intensity of the
glomerular IgA deposits. Clinically, however, more than 30%
of the patients may have exclusive glomerular IgA deposits in
the absence of IgG and IgM.3 Thus, there is a need to
establish an animal model for IgAN for identification of
pathogenic events or factors associated exclusively with
glomerular IgA deposits. Passive administration of IgA and
specific antigen for the in vivo induction of glomerular
IgA-IC deposits is a well-established experimental IgAN
model.4,10 In this model, glomerular IgA and C3 deposits
develop within 24 h in glomeruli of mice that received IgA
anti-phosphorylcholine (PC) intraperitoneally and pneumo-
coccal C-polysaccharide (PnC) intravenously.11 However, we
also observed marked glomerular deposits of IgM and IgG
that develop within short period after the IgA-IC deposition.
Thus, an endogenous immune response may produce
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significant amounts of IgM-IC and IgG-IC that could
modulate the glomerular response to IgA-IC.
Glomerular infiltration of monocytes/macrophages
(Mon/Mf) is frequently observed in IgAN and other
forms of human GN.12–16 Tubulointerstitial cells infiltrates,
in particular, correlate with disease progression.17 In these
lesions the most commonly implicated chemokine in renal
Mon/Mf recruitment is monocyte chemoattractant protein-
1 (MCP-1).18 Interleukin-6 (IL-6) is produced by a wide
variety of cells also including Mon/Mf and play a major role
in mesangial proliferative disease, and in IgAN, in particular.
In the present study we postulated that IgAN model in B-cell-
deficient (BCD) mice is useful to test the role of exclusive IgA
immune deposits play in induction of glomerular injury and
such model will be able to discern the relationship between
IgA-IC and subsequent cellular immune response and Mon/
Mf glomerular infiltration leading to progression of IgAN.
RESULTS
Induction of glomerular immune deposits
To examine experimental IgA immune deposits under condi-
tions that recapitulate the pattern observed in human disease,
immune complex formation was induced in vivo by
simultaneous administration of IgA anti-PC (intraperitoneal)
and PnC (intravenous). Only glomerular deposits of IgA and
C3 were observed on day 14 in BCD after treatment with
IgAþ PnC (Figure 1a–d). In contrast, similarly treated WT
mice showed strong IgG and IgM codeposits of IgA and C3
(Figure 1e–h). Normal BCD and WT mice did not show any
IgA deposits. Also none of the BCD mice that received the
PnC antigen only showed any glomerular IgA, IgG, IgM, or
mesangial C3 deposition (Figure 1i–l). In contrast, WT mice
that received PnC only showed an extensive glomerular
deposition of IgG and IgM along with IgA and C3 (Figure
1m–p). As shown in Figure 1q, semiquantitative analysis of
the immunofluorescence intensity of the immune deposits in
the immune complex-treated WT mice showed a significantly
enhanced glomerular deposition of IgA, IgG, IgM, and C3
compared with BCD mice (Po0.05).
The composition of IgG subclasses in the immune
deposits were also identified in the WT mice treated with
IgAþ PnC for 14 days (Figure 2a). Semiquantitative analysis
of the isotype intensity (Figure 2b) revealed IgG2b as the
major constituent of the immune deposits with lesser but
equivalent intensity of IgG1 and IgG3.
Renal pathogenesis and dysfunction
Onset of glomerular injury appeared between day 3 and 7 in
both experimental groups BCD and WT that received
IgAþ PnC. The proliferative lesion progressed into necrosis,
sclerosis and crescent formation by day 14 only in the BCD
group (Figure 3a). Surprisingly, the BCD mice treated with
IgAþ PnC showed significantly more severe glomerular
injury than WT groups at all the stages of progression
(Figure 3b). In addition to the glomerular lesions, a variety of
severe tubulointerstitial changes on day 14 were also observed
in BCD mice, including focal tubular atrophy, tubulointer-
stitial inflammation, proteinaceous casts, and occasional
erythrocyte casts within the tubules.
Although the administration of PnC into BCD mice
showed no glomerular immune deposits, significant glomer-
ular proliferation and sclerosis occurred in this group. In
contrast, and despite the intense IgG, IgM, and C3
glomerular deposits in the WT mice that received PnC only,
the glomerular lesion was mild by all the evaluating criteria
and significantly less than any other group.
The earliest indication of renal dysfunction in the
IgAþ PnC-treated BCD mice was significant increase in
blood urea nitrogen on day 7 (Figure 3c). The level of blood
urea nitrogen kept increasing with progression in renal injury
in this group.
The time course pattern of proteinuria appeared to track
the development of glomerular lesions (Figure 3d). The BCD
and WT mice that received PnC only failed to develop
significant levels of proteinuria. The levels of serum
creatinine revealed no significant difference among the
BCD and WT mice on days 3, 7, and 14.
Influence of B and T cells on IgA-IC-mediated renal injury
The unexpected severity of the glomerular lesions in
BCD mice prompted similar examination in B-and T-cell-
deficient RAG-1 mice. As shown in Figure 4a and b, the
IgAþ PnC failed to precipitate in glomerular injury in
RAG-1 mice compared with the WT controls (B6.129SF2).
These data emphasize the requirement for T cells in IgA-
IC-mediated GN.
Antibody immune response
The serum level of IgA, IgG, and IgM anti-PC in response to
PnC was determined by enzyme-linked immunosorbent assay
(ELISA). As expected, treatment of BCD mice with PnC
alone or with IgAþ PnC showed no antibody response. In
contrast, treatment of WT mice with PnC or IgAþ PnC
elicited a rapid and enhanced production of IgM and IgG
anti-PC response that persisted throughout the course of the
disease induction.
Activation of B cells
To determine whether B cells were activated in the WT
mice that received PnC or IgAþ PnC, fluorocytometric
analysis was performed on spleen lymphocytes. Spleen
cells were double stained with anti-CD19 antibody,
marker of B cells, and anti-CD69 antibody, a surface marker
of cell activation. CD19þ B cells of WT mice that were
treated with PnC only showed rapid and high level of
activation throughout the study period (Figure 5). The WT
mice treated with IgAþ PnC also expressed heightened
CD69 on days 3, 7, and 14, but at significantly lower
level than the PnC only group, suggesting the IgA anti-PC
attenuated the B-cell response. As expected, only scant
CD19þ /CD69þ B cells were found in experimental and
control group of BCD mice.
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Activation of T cells
Cytofluorometric analysis for CD3 and CD69, markers of
activated T cells, was also performed to determine whether T
cells were activated during the development of the IgAN. As
shown in Figure 6, marked elevation of activated T cells
developed in the BCD group that received IgAþ PnC on days
3 and 7 and was attenuated by day 14. In contrast, the
IgAþ PnC treatment of the WT resulted only in minimal
increase observed on day 3 that was not sustained throughout
the remainder of the observation period. The most remark-
able finding was the rapid and very high level (28.773.4%)
of activated T cells on day 3 in the BCD group treated with
PnC only. Although the level of activation declined by 40%
on day 7, it remained significantly higher than any other
group including the WT group that received PnC only.
Glomerular leukocytic infiltration
To determine whether glomerular macrophages and
neutrophils are elicited in response to PnC treatment, we
enumerated the influx of CD11bþ in BCD and WT mice in
time course evaluation (Figure 7). As represented in Figure
7a, glomerular infiltration with CD11bþ cells was evident
early on day 3 in both BCD and WT mice and persisted
in accumulation throughout the examined time course.
300 BCD
WT
250
200
150
100
50
To
ta
l f
lu
or
es
ce
nc
e 
sc
or
e
0
IgA
*
**
**
*
IgG IgM C3
IgA IgG IgM C3
BCD/IgA+PnC
WT/IgA+PnC
BCD/PnC
WT/PnC
a b c d
e f g h
i j k l
m n o p
q
Figure 1 | Comparison of the glomerular immune deposits composition associated with IgAþPnC in BCD and WT mice. Representative
immunofluorescence micrographs of IgA, IgG, IgM, and C3 in the kidneys at day 14 treatment of (a–d) BCD and (e–h) WT mice with
IgAþ PnC are compared to (i–l) BCD mice and (m–p) WT mice that received PnC only. Original magnification  400. (q) Semiquantitative
analysis of the immunofluorescence intensity in renal tissues of the experimental groups of BCD and WT mice treated with IgAþ PnC.
*Po0.05; **Po0.005.
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However, significantly higher number of CD11bþ in BCD
than in WT was observed on days 7 and 14 (Figure 7b).
To determine the effect of IgAþ PnC immune deposits in
BCD mice and the accompanying glomerular co-deposits of
IgG and IgM in WT group, glomerular CD11bþ and
polymorphonuclear neutrophil (PMN) were quantified on
day 14. As illustrated in Figure 7c, surprisingly, both
macrophages and PMN were significantly less in the
IgAþ PnC groups than in their counterparts that received
PnC only. These data suggest that number of macrophages
and PMN glomerular infiltrate does not correlate with the
extent of injury associated with IgAþ PnC deposits.
In addition to macrophages, T cells are associated with
rapidly progressive GN. BCD mice showed increased CD3þ
T cells glomerular infiltration on day 14 after the injection of
IgAþ PnC (Figure 8a). Infiltration of CD3þ T cells were
observed predominantly in the periglomerular region and
interstitial tissue. In contrast, fewer CD3þ T cells were
detectable in glomeruli, periglomerular region and interstitial
tissue of WT mice treated with IgAþ PnC (Figure 8b).
There was focal mild T cells renal interstitial infiltration in
the BCD and WT groups treated with PnC only (Figure 8a).
These findings indicate that CD3þ T cells infiltration
into the kidney was associated with the greater severity
of the glomerular lesions in experimental BCD mice with
IgAþ PnC immune deposits.
Effect of PnC and IgA immune deposits on IL-6
The inflammatory response in this model induced us to
examine the serum level of IL-6. As shown in Figure 9a,
IgAþ PnC treatment induced gradual increase in the serum
level of IL-6 that became markedly elevated by day 14. In
contrast, IgAþ PnC treatment had insignificant effect on
serum level of IL-6 in WT mice. Expression of IL-6 in renal
tissue in response to IgAþ PnC immune deposits was
examined by reverse transription-polymerase chain reaction
RT-PCR (Figure 9b). In the BCD group, amplified PCR
transcripts were detected on day 7 and declined by day 14.
This unexpected decreased in renal expression, prompted
quantitative RT-PCR (qRT-PCR) analysis of glomeruli
isolated from BCD and WT experimental and control
groups. As shown in Figure 9c, the BCD glomerular IL-6
was markedly elevated in response to IgAþ PnC. Immuno-
histochemical analysis of the renal tissues on day 14, revealed
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Figure 2 | The subclass isotypes of IgG immune deposits associated with IgAþPnC in WT mice. (a) Representative immunofluorescence
micrographs of IgG1, IgG2b, and IgG3 in the kidneys at day 14 treatment of WT mice with IgAþ PnC are compared to normal controls. Original
magnification  400. (b) Semiquantitative analysis of the immunofluorescence intensity for IgG1, IgG2b, and IgG3 in renal tissues of the
experimental groups of WT mice treated with IgAþ PnC. *Po0.05; **Po0.005.
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Figure 3 | Time course comparison of the glomerular histopathologic changes and renal function associated with IgAþPnC or PnC
only. (a) Glomerular morphology of BCD mice and WT mice treated with IgAþ PnC or PnC alone on day 0 (normal), day 3, day 7, and day 14 of
treatment. Original magnification  400. (b) Semiquantitative analysis of cellular proliferation, glomerulosclerosis, cellular necrosis, and
crescent formation in glomeruli of BCD and WT mice treated with IgAþ PnC or PnC only. Influence of IgAþ PnC or PnC alone on renal function
as assessed by measurement of (c) blood urea nitrogen and (d) urinary protein.
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intense glomerular IL-6 staining in the BCD mice and much
weaker glomerular pattern in the WT (Figure 9d). These
data suggest that IgAþ PnC induce glomerular IL-6 and
this induction is downregulated by endogenous IgG and IgM
co-deposits in the glomeruli of WT mice.
Effect of PnC and IgA immune deposits on MCP-1
Recruitment of Mon/Mf to the inflammatory site is usually
attributed to MCP-1, accordingly the serum level of MCP-1
was compared in both BCD and WT mice after IgAþ PnC
treatment (Figure 9e). In the BCD group, rapid and marked
elevation, 200-fold, was observed by day 3 with further
increase on day 7 that persisted to day 14. Significantly lower
level of MCP-1 but similar pattern was detected in WT mice
response to IgAþ PnC treatment.
Renal expression of MCP-1 (Figure 9f) in response to
IgAþ PnC immune deposits increased rapidly on day 3
and persisted throughout the 14 days. The WT mice
also showed rapid increase in renal MCP-1 expression that
was weaker than the BCD group. Analysis by qRT-PCR
(Figure 9g) of isolated glomeruli from the different groups
showed significant increase in the glomerular expression in
the BCD group. Immunohistochemical analysis of the renal
tissues on day 14 showed very strong glomerular and
interstitial MCP-1 staining in the BCD mice whereas the
WT group displayed only glomerular pattern (Figure 9h).
Activation of NF-jB by glomerular IgA immune deposits
Although mesangial proliferation and glomerulosclerosis are
prominent histopathologic features of IgAN, the molecular
events underlying these lesions are not known. Phosphoryla-
tion of NF-kB p65(RelA) is required for optimal induction of
NF-kB target genes in response to a variety of proinflamma-
tory stimuli that lead to inflammation. Thus, we compared
NF-kB activation in the glomeruli of BCD and WT of PnC
and IgAþ PnC-treated groups using a specific antibody
to phosphorylated-NF-kB p65 (Ser276). Normal kidneys
from either strain of mice showed little or no staining
for activated NF-kB p65 (Figure 10a). In contrast, the
staining pattern was markedly increased in the BCD group at
3 days after IgAþ PnC induction and continued to intensify
with time (Figure 10b). By comparison, the WT groups
showed less NF-kB p65 activation during the same time
period. Enumeration of phosphorylated-NF-kB p65þ cells/
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Figure 5 | Activation of B cells (CD19þ /CD69þ ) by PnC and its modulation by IgA anti-PnC. (a) Immunofluorescence dot plot pattern
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gcs (Figure 10b) in time course studies revealed patterns that
paralleled those observed for glomerular injury and renal
function. The correlation coefficients between activation of
NF-kB and severity of glomerular lesions and renal dysfunc-
tion are summarized in Table 1. These data demonstrate that
NF-kB activation is an underlying mechanism through which
IgAþ PnC immune deposits induce renal injury and
dysfunction.
DISCUSSION
The lack of correlation between the intensity of the IgA
immune deposits and the extent of glomerular injury in
human disease suggest that critical factors, other than the
IgA, play an important role in pathogenesis. The presented
data permit a conclusion that the antigen in IgA-IC is a
critical mediator whose nephritogenic potential is modulated
by the acquired antibody and cell-mediated response.
Several other points need to be addressed in view of the
presented data. Foremost, there is an apparent contradiction
between the well-established role of IgG-IC in induction of
tissue injury and our findings that in WT mice, intense
glomerular IgG immune deposits by endogenous anti-
body response to the administered PnC antigen failed
to induce renal injury (Figure 3). Additionally, in WT mice
with passively induced IgAþ PnC, the intense IgG and C3
co-deposits appeared to attenuate rather enhance renal
injury, compared to the exclusive IgAþ PnC immune
deposits of BCD mice (Figure 3). Thus, it appears that the
IgG and IgM response modulated favorably the course of
IgAN. These effects may have resulted from rapid immune
elimination of the PnC from circulation by IgG or IgM or
the masking of the PnC nephritogenic determinants by the
endogenous IgG and IgM.
Additional mechanisms might have attenuated glomerular
injury by the endogenous antibody response. These involve
IgG–PnC complexes binding to FcgRIIb receptors on
mesangial cells and macrophages with the resultant signaling
through the immunoreceptor tyrosine-based inhibitory motif
(ITIM) hindering the inflammatory response.19–21 In this
regard, it is important to point out that the major IgG
subclass constituents of the IgA immune co-deposits were
IgG2b and IgG1 (Figure 2). Both these isotypes are
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characterized by high affinity for the inhibitory FcgRIIb.22
These findings are consistent with the recent report by
Nimmerjahn and Ravetch23 demonstrating the influence of
the IgG subclasses on activating-to-inhibitory Fc receptor
binding on immune-complex-mediated response. These data
are highly consistent with experimental and clinical findings
demonstrating the favorable effect of administering IgG on
experimental immune complex GN and clinical IgAN.24–26
The strong T-cell activation by PnC, a thymus-indepen-
dent type 2 antigen, was rather unexpected in its magnitude
and similarity to a superantigen. As the PnC is a
polysaccharide and with no known specific T-cell receptor,
it is most likely that T-cell activation by PnC may have
occurred through the MHC class I-like molecule, CD1d on
antigen-presenting cells (APCs) has been recently reported.27
Furthermore, PnC as a bacterial antigen may have activated
the APC through Toll-like receptor (TLR) that provided
further activation signals that amplified the presentation to T
cells. Influence of such T-cell activation on the course of
IgAN can only be postulated. Abnormalities in T lympho-
cytes activity and production of cytokines have been reported
in patients with IgAN.28–33 Although the link between T cells
and glomerular injury is not clearly defined, in experimental
IgAN model, Montinaro et al.34 demonstrated that extra-
renal interferon-g, a T-cell cytokine, aggravated the glomer-
ular response to IgA immune deposits. It is well recognized
that T cells and macrophages glomerular infiltration is
associated with rapidly progressive GN.35–40 Conversely,
induction of IgAþ PnC glomerular deposition in T-and B-
cell-deficient RAG-1 mice failed to precipitate in glomerular
injury. Collectively these findings suggest that T cells are
required for induction and progression of IgAN.
Several studies reported the detection and prognostic
value of IL-6 in IgAN patients.41–45 Surprisingly, in our model
the increase in the level of circulating IL-6 occurred late in
the sera of the experimental BCD group and did not change
significantly in WT mice (Figure 9a). Although the renal
expression of IL-6 as detected by RT-PCR was relatively weak
in both groups (Figure 9b), it is evident from the high
expression (Figure 9c) and strong immunohistochemical
staining of glomeruli in BCD mice (Figure 9d) that IL-6 plays
an important role in pathogenesis.
The chemokine MCP-1 is also implicated in the
pathogenesis of IgAN.45–48 Rapid and dramatic increase in
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circulating MCP-1 level developed in BCD mice treated with
IgAþ PnC (Figure 9e). Total renal tissue and glomerular
expression of MCP-1 similarly increased (Figure 9f and g)
and temporally coincided with elevated circulating level and
strong immunohistochemical staining in the BCD group
(Figure 9h). The glomerular inflammatory response
prompted us to examine the activation of inflammatory
NF-kB transcription factor. We detected rapid increase in the
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Figure 10 | Activation of NF-jB in the glomeruli associated with IgAþPnC immune deposition. (a) Representative immunohistochemical
detection of Phospho-NF-kB/p65 immunostaining in glomeruli. The sections from BCD mice and WT mice on day 0 (normal), day 3, day 7,
day 14 treated with IgAþ PnC or PnC alone was probed with phospho-NF-kB/p65 antibody. Original magnification  400. (b) Semiquantitative
analysis of glomerular phospho-NF-kB/p65þ cells in BCD mice and WT mice treated with IgAþ PnC or PnC alone.
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level of the NF-kB activation in the glomeruli of the
experimental BCD group treated with IgAþ PnC (Figure
10). The progressive increase in NF-kB activation during the
course of 14 days treatment with IgAþ PnC correlated
strongly with extent of glomerular injury and renal dysfunc-
tion in both BCD and WT groups (Table 1). These findings
are highly consistent with the clinical studies in IgAN.49–51
In conclusion, the antigen-dependent glomerular injury
associated with IgA immune deposits is governed by the
adaptive immune response to the antigen. Activation of T
cells by the antigen is associated with an enhancement of
renal injury. Conversely, the endogenous IgG and IgM
response to the antigen abated the cellular response and
attenuated the glomerular inflammatory burden. Thus, the
pathogenesis of IgAN is governed by the balance of systemic
immunity and local renal response.
MATERIALS AND METHODS
Preparation of IgA-IC
IgA anti-PC was purified from TEPC-15 ascites by using affinity
chromatography on PC-Sepharose 4B as previously described.52
PnC was purified from Streptococcus pneumoniae and used as
previously described.10
Induction of IgAN
The BCD mice (B6.129S2-Igh-6tm1Cgn/J) and WT C57BL/6 were
obtained originally from The Jackson Laboratory (Bar Harbor, ME)
and the colony maintained at the animal center of the Academia
Sinica, Taipei, Taiwan, Republic of China. The RAG-1 mice
(B6;129S7-Rag1tm1Mom/J) with combined B-and T-cell deficiency
and corresponding WT B6.129SF2 mice were purchased from The
Jackson Laboratory.
Glomerular IgA immune deposits were induced by daily
intraperitoneal injection of purified IgA anti-PC (1.5 mg), then
intravenous injection of PnC (100 mg), 2 h later, into groups of mice,
three animals per group. Mice were killed at 3, 7, and 14 days after
the administration of purified IgA anti-PC and PnC. Mice treated
with PnC only served as antigen controls.
Renal function and histopathological evaluation
Renal function evaluation, histologic examination, immunofluores-
cence staining, immunohistochemical analysis, morphologic evalua-
tion, and scoring were described previously in detail.53
For immunofluorescence staining and immunohistochemistry,
the following antibodies were used. Fluorescein isothiocyanate-
conjugated (FITC) goat anti-mouse IgA, IgG, IgM, and C3 (Sigma,
St Louis, MO, USA), and FITC-conjugated goat anti-mouse IgG1,
IgG2b, and IgG3 (SouthernBiotech, Birmingham, AL, USA). Rat
anti-mouse CD3 antibody (BD Pharmingen, San Diego, CA,
USA). Rabbit anti-mouse MCP-1 antibody and rat anti-mouse
macrophage CD11b antibody (Serotec Ltd., Kidlington, Oxford,
UK). Rat anti-mouse IL-6 antibody (R&D, Minneapolis, MN, USA).
Anti-mouse Phospho-NF-kB/p65 (Ser276) antibody (Cell signaling,
Danver, MA, USA).
Gene expression analysis
The RT-PCR was performed as previously described.53 The
PCR-specific primer pairs used for analysis were as follows: GAPDH
(50-TCC GCC CCT TCT GCC GAT G-30; 50-CAC GGA AGG CCA
TGC CAG TGA-30), IL-6 (50-ATG AAG TTC CTC TCT GCA AGA
GAC T-30; 50-CAC TAG GTT TGC CGA GTA GAT CTC-30), and
MCP-1 (50-AGG TCC CTG TCA TGC TTC TGG-30; 50-ACA GTC
CGA GTC ACA CTA GTT CA-30).
Glomeruli isolation and analysis
Isolation of glomeruli was performed as described previously, using
a standard three-stage sieving method.54 Real-time PCR was
performed as previously described.53 Briefly, a real-time PCR was
performed using Bio-Rad iQ SYBR Green supermix with Opticon
(MJ Research, Inc., Waltham, MA, USA), according to manufac-
turer’s instructions. Reaction specificity was confirmed by gel
electrophoresis of products after real-time PCR and melting curve
analysis. Ratios for IL-6/GAPDH and MCP-1/GAPDH mRNA were
calculated for each sample.
Serologic studies
The serum in BCD mice and C57BL/6 mice were tested by enzyme-
linked immunosorbent assay for the presence of IgA anti-PC, IgG
anti-PC, and IgM anti-PC antibody to PnC. PnC was coated
onto 96-well plates. Diluted serum samples were added to the
BSA-blocked wells. After washing, peroxidase-conjugated goat anti-
mouse IgA, IgG, and IgM antibodies were added. Finally, the
substrate tetramethylbenzidine was added and absorbance at 450 nm
was measured. The expression levels of IgA anti-PC, IgG anti-PC,
and IgM anti-PC were quantified by ratio of the diseased group to
the normal control group. The mean level of the normal control
group was designated as an arbitrary value of 1. Each sample
was analyzed in duplicate. ELISA of serum IL-6 and MCP-1
was performed using a kit (BD Pharmingen, San Diego, CA, USA)
and levels were expressed as picograms of IL-6 or MCP-1 per
millimeter of serum.
Flow cytometry
The spleen was removed and cell suspension was prepared and
rendered free of erythrocytes by osmotic lysis. The splenocytes were
incubated with anti-mouse CD3-FITC, CD19-FITC, and anti-mouse
CD69-phycoerythrin (PE) (BD Pharmingen, San Diego, CA, USA).
Flow cytometric analysis was performed as described previously.55 In
Table 1 | Summary of the correlation coefficients (r-value) between the extent of NF-jB activation (p65+ cells/gcs) and
development of glomerular injury and renal dysfunction in IgA+PnC or PnC-treated BCD and WT mice
Glomerular injury Renal function
Proliferation Sclerosis Necrosis Crescents Proteinuria BUN
BCD IgA+PnC 0.975 0.923 0.944 0.835 0.845 0.947
WT IgA+PnC 0.924 0.984 0.966 0.986 0.966 0.993
BCD PnC 0.949 0.818 0.923 0.875 0.821 0.942
WT PnC 0.931 0.799 0.838 0.764 0.835 0.760
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the CD3þ or CD19þ /CD69þ lymphocytes, a dot plot pattern was
performed according to FITCþ /PEþ intensity, to determine the
positive cell ratio. The percentage of FITC- and PE-positive cells was
measured by a FACSscan using the CELLQUEST program (Beckton
Dickinson, San Jose, CA, USA).
Statistics
Values are presented as mean7s.d. for three mice in each group.
Except where noted, comparison among groups were performed by
analysis of variance and between two groups by Student’s t-test.
Statistically difference was considered when Po0.05. Regression
analysis was used to determine the correlation coefficient between
NF-kB score and other parameters.
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